Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
KM, Meiji Initiate PIII Pediatric Trial for XBB.1.5-Adapted COVID Vaccine
KM Biologics and Meiji Seika Pharma said on December 6 that they have kicked off a domestic PIII pediatric clinical trial of the inactivated vaccine “KD-414 (XBB.1.5)” against the COVID-19 Omicron variant XBB.1.5. The trial, launched the previous day, will…
To read the full story
Related Article
- Meiji/KM’s XBB.1.5-Tailored COVID Jab to Enter Pediatric PIII Study
October 17, 2023
- KM Biologics to File COVID Jab in Japan Spring 2023: Official
November 29, 2022
BUSINESS
- Tremfya SC Induction Seen Cutting Hospital Time in UC: Expert
March 24, 2026
- Padcev-Keytruda under EMA Review for Cisplatin-Eligible Perioperative MIBC
March 24, 2026
- Nippon Kayaku, GlycoNex Ink Pact on Next-Gen ADC Candidate
March 24, 2026
- Celltrion Wins First Xolair Biosimilar Approval in Japan, Targets May Listing
March 24, 2026
- Roche-Chugai Drops Emugrobart for SMA, FSHD; Obesity Program to Continue
March 24, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…